CKPT - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Checkpoint Therapeutics Inc. (CKPT) | Benzinga

LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ:CKPT) securities between March 10, 2021 and December 15, 2023, inclusive (the "Class Period").

If you suffered a loss on your Checkpoint investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Checkpoint-Therapeutics-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On December 18, 2023, Checkpoint disclosed that the U.S. Food and Drug Administration ("FDA") had not approved the Biologics License Application ("BLA") that the Company had submitted for its metastatic cutaneous squamous cell carcinoma ("cSCC") treatment, cosibelimab. Specifically, the Company stated ...

CKPT)>Full story available on Benzinga.com